Teva Pharmaceutical Industries ADR (TEVA) Stock Price, Quote & News

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 914 8213

Website: www.tevapharm.com

Address:

124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel

OX50 Feb. 25 at 9:12 PM

$TEVA No winner between the patent ruling from the court between CORT and TEVA. Both went down. I own both stocks by 15000 shares and 20,000 shares.

1 · Reply

SdotRayborn Feb. 25 at 9:09 PM

$TEVA I can’t believe the volume. Extremely out of the ordinary 👀

1 · Reply

Makingmillions192 Feb. 25 at 7:37 PM

$LEXX News leak? $TEVA $LLY $NVO

0 · Reply

layahoo Feb. 25 at 12:25 AM

$TEVA Just announced: Conferences: Tuesday, March 3, 2026 (investor meetings only – no webcast) Leerink Partners Global Healthcare Conference Monday, March 9, 2026, at 10:00 am ET (webcast fireside chat) Barclays 28th Annual Global Healthcare Conference Tuesday, March 10, 2026, at 8:00 am ET (webcast fireside chat)

0 · Reply

hitmongreen Feb. 24 at 9:14 PM

$BAX this thing never seems to want to take off. Chart reminds me of $TEVA back during 19-22 Gonna be here a while it seems. Thoughts??

0 · Reply

shoagh12 Feb. 24 at 6:48 PM

$TEVA 40$ soon

0 · Reply

Makingmillions192 Feb. 24 at 2:01 PM

$JAZZ $LEXX $MRK $TEVA

0 · Reply

Nomorelies Feb. 24 at 1:21 PM

$TEVA Strange chart.

2 · Reply

Hopewisper Feb. 24 at 7:02 AM

$TEVA I'm waiting and ....

0 · Reply

Hopewisper Feb. 24 at 7:00 AM

$TEVA Terrordomo homo from the 80'.... after 5 $

0 · Reply

Teva to Present at the Upcoming Investor Conferences in March

2026-02-23T13:48:16.000Z - 2 days ago

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

2026-02-21T14:55:21.000Z - 4 days ago

Teva (TEVA) Advances Schizophrenia Treatment with FDA Application

2026-02-21T14:09:02.000Z - 4 days ago

Teva, Medincell granted FDA review for long-acting antipsychotic

2026-02-21T06:31:14.000Z - 5 days ago

FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment

2026-02-20T20:25:33.000Z - 5 days ago

Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application

Fri, 20 Feb 2026 14:43:00 -0500 - 5 days ago

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

2026-02-20T15:00:36.000Z - 5 days ago

Price Over Earnings Overview: Teva Pharmaceutical Indus

Fri, 20 Feb 2026 00:45:00 -0500 - 6 days ago

Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

2026-02-19T16:48:26.000Z - 6 days ago

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

2026-02-19T16:10:48.000Z - 6 days ago

Corcept falls as appeals court sides with Teva in Korlym patent dispute

2026-02-18T16:02:18.000Z - 7 days ago

Truist Securities Raises Price Target for TEVA, Maintains Buy Rating | TEVA Stock News

2026-02-17T17:02:25.000Z - 8 days ago

Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow

2026-02-17T15:54:57.000Z - 8 days ago

Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript

2026-02-17T14:22:25.000Z - 8 days ago

Sanofi, Teva Report Positive Phase 2b Results For Duvakitug

2026-02-17T12:47:27.000Z - 8 days ago

Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's

2026-02-17T12:04:37.000Z - 8 days ago

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Tue, 17 Feb 2026 07:04:37 -0500 - 8 days ago

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

2026-02-17T11:56:32.000Z - 8 days ago

Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's

2026-02-17T11:15:51.000Z - 8 days ago

Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease

2026-02-17T11:00:00.000Z - 8 days ago

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

2026-02-17T11:00:00.000Z - 8 days ago

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Tue, 17 Feb 2026 06:00:00 -0500 - 8 days ago

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

2026-02-14T00:30:31.000Z - 12 days ago

Harel Insurance Investments & Financial Services Ltd. ...

2026-02-11T15:52:41.000Z - 14 days ago

Noteworthy ETF Inflows: SPDW, SPOT, SE, TEVA

2026-02-09T18:32:09.000Z - 16 days ago

TEVA: Goldman Sachs Raises Price Target to $45, Maintains Buy Rating | TEVA Stock News

2026-02-05T19:06:57.000Z - 20 days ago

Teva (TEVA) Q4 2024 Earnings Call Transcript

2026-02-05T19:06:23.000Z - 20 days ago

Teva (TEVA) Q3 2024 Earnings Call Transcript

2026-02-05T19:00:30.000Z - 20 days ago

A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings

2026-02-05T16:08:50.000Z - 20 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Down 0% on Feb 5

2026-02-04T05:02:42.000Z - 22 days ago

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

2026-02-03T16:11:56.000Z - 22 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Shares Up 3.39% on Feb 3

2026-02-03T15:57:28.000Z - 22 days ago

Notable ETF Inflow Detected - IDEV, SPOT, SE, TEVA

2026-02-01T23:40:21.000Z - 24 days ago

Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

2026-01-30T16:38:21.000Z - 26 days ago

Barclays Raises Price Target for TEVA to $38, Maintains Overweight Rating | TEVA Stock News

2026-01-29T21:03:41.000Z - 27 days ago

Teva snaps six straight sessions of gains

2026-01-29T16:02:02.000Z - 27 days ago

Scotiabank Raises TEVA Price Target to $40 | TEVA Stock News

2026-01-29T15:37:29.000Z - 27 days ago

Truist Securities Raises Teva Pharmaceutical (TEVA) Price Target to $38.00 | TEVA Stock News

2026-01-29T00:47:11.000Z - 4 weeks ago

Teva CEO Richard Francis sits down with Jim Cramer

2026-01-28T19:53:42.000Z - 4 weeks ago

Teva (TEVA) Q3 2025 Earnings Call Transcript

Wed, 28 Jan 2026 14:02:19 -0500 - 4 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript

Wed, 28 Jan 2026 12:22:42 -0500 - 4 weeks ago

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

2026-01-28T17:22:42.000Z - 4 weeks ago

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

2026-01-28T16:01:46.000Z - 4 weeks ago

Teva Pharmaceutical Industries Limited 2025 Q4 - Results - Earnings Call Presentation

2026-01-28T14:45:32.000Z - 4 weeks ago

Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals

2026-01-28T14:34:43.000Z - 4 weeks ago

TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals

2026-01-28T14:31:22.000Z - 4 weeks ago

TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies

2026-01-28T14:30:04.000Z - 4 weeks ago

Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say

2026-01-28T14:02:49.000Z - 4 weeks ago

TEVA Aims to Double Biosimilar Revenue by 2027

2026-01-28T13:54:24.000Z - 4 weeks ago

TEVA: Progress in Transformation Initiatives and Future Financial Expectations

Jan 28, 2026, 7:31 AM EST - 4 weeks ago

Teva Pharmaceutical profit, revenue rise in fourth quarter

Jan 28, 2026, 7:00 AM EST - 4 weeks ago

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Jan 27, 2026, 8:00 AM EST - 4 weeks ago

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

Jan 14, 2026, 5:02 PM EST - 6 weeks ago

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 8:01 AM EST - 6 weeks ago

Teva Is No Longer A Turnaround Story, It's A Growth One

Jan 13, 2026, 2:46 PM EST - 6 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 12:26 PM EST - 6 weeks ago

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

RPRX

Jan 12, 2026, 10:46 AM EST - 6 weeks ago

Why Investors Are So Optimistic on Teva

Jan 11, 2026, 6:00 PM EST - 6 weeks ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 5:00 PM EST - 6 weeks ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 5, 2026, 4:30 PM EST - 7 weeks ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 8:58 AM EST - 7 weeks ago

Top 2 Health Care Stocks That May Crash In Q1

EXAS

Dec 24, 2025, 8:36 AM EST - 2 months ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 23, 2025, 6:08 PM EST - 2 months ago

Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)

Dec 19, 2025, 3:40 AM EST - 2 months ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Dec 9, 2025, 8:00 AM EST - 2 months ago

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dec 4, 2025, 2:08 PM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 8:10 AM EST - 3 months ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Nov 21, 2025, 4:30 PM EST - 3 months ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Nov 19, 2025, 8:07 AM EST - 3 months ago

Teva seeks startups to help solve global pharmaceutical challenges

Nov 18, 2025, 8:58 AM EST - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 14, 2025, 10:38 AM EST - 3 months ago

Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business

Nov 10, 2025, 2:51 PM EST - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 6:00 PM EST - 3 months ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 5, 2025, 1:02 PM EST - 4 months ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:01 PM EST - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 11:30 AM EST - 4 months ago

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Nov 5, 2025, 9:14 AM EST - 4 months ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 7:44 AM EST - 4 months ago

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Nov 5, 2025, 7:00 AM EST - 4 months ago

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Oct 31, 2025, 4:30 PM EDT - 4 months ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 30, 2025, 11:45 AM EDT - 4 months ago

Blood pressure medicine recalled over high levels of cancer-causing chemical

Oct 20, 2025, 4:30 PM EDT - 4 months ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 17, 2025, 12:18 PM EDT - 4 months ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

VTRS

Oct 10, 2025, 3:00 PM EDT - 4 months ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 7, 2025, 4:07 AM EDT - 5 months ago

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Sep 25, 2025, 4:30 PM EDT - 5 months ago

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 5 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 11:42 AM EDT - 5 months ago

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Sep 24, 2025, 7:23 AM EDT - 5 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 22, 2025, 2:53 PM EDT - 5 months ago

Teva Pharmaceutical Industries Limited - Special Call

Sep 20, 2025, 10:15 PM EDT - 5 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

OX50 Feb. 25 at 9:12 PM

$TEVA No winner between the patent ruling from the court between CORT and TEVA. Both went down. I own both stocks by 15000 shares and 20,000 shares.

1 · Reply

SdotRayborn Feb. 25 at 9:09 PM

$TEVA I can’t believe the volume. Extremely out of the ordinary 👀

1 · Reply

Makingmillions192 Feb. 25 at 7:37 PM

$LEXX News leak? $TEVA $LLY $NVO

0 · Reply

layahoo Feb. 25 at 12:25 AM

0 · Reply

hitmongreen Feb. 24 at 9:14 PM

$BAX this thing never seems to want to take off. Chart reminds me of $TEVA back during 19-22 Gonna be here a while it seems. Thoughts??

0 · Reply

shoagh12 Feb. 24 at 6:48 PM

$TEVA 40$ soon

0 · Reply

Makingmillions192 Feb. 24 at 2:01 PM

$JAZZ $LEXX $MRK $TEVA

0 · Reply

Nomorelies Feb. 24 at 1:21 PM

$TEVA Strange chart.

2 · Reply

Hopewisper Feb. 24 at 7:02 AM

$TEVA I'm waiting and ....

0 · Reply

Hopewisper Feb. 24 at 7:00 AM

$TEVA Terrordomo homo from the 80'.... after 5 $

0 · Reply

Hopewisper Feb. 23 at 7:04 PM

$TEVA I only go for a Carlsberg....

2 · Reply

Hopewisper Feb. 23 at 7:03 PM

$TEVA Ohhh no not again ..... Terror drunk on millers ...

1 · Reply

layahoo Feb. 23 at 6:45 PM

$TEVA I'm adding here:)))

0 · Reply

Terrordomo80 Feb. 23 at 2:46 AM

$TEVA Big Druckenmiller who took this gem up just slashed it by 64.6%. It was a good run...Hope you all enjoyed the run as it resets now...

1 · Reply

layahoo Feb. 20 at 9:23 PM

$TEVA U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) said on Friday that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension or TEV-'749 for the treatment of schizophrenia in adults. The application was based on data from a late-stage trial in which TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations and showed no evidence for the need for post-injection monitoring.

1 · Reply

StocktwitsNews Feb. 20 at 8:18 PM

Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment $TEVA $IEFA $EFA https://stocktwits.com/news/equity/markets/teva-pharmaceuticals-seeks-fda-greenlight-for-schizophrenia-treatment/cZRNir1R4xt

0 · Reply

TheDudeRooster Feb. 20 at 4:17 PM

$TEVA Great morning scalp week $2.13 a share. Have a good weekend!

0 · Reply

StocktwitsNews Feb. 19 at 7:34 PM

CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight $CORT $IJR $VTI $TEVA https://stocktwits.com/news/equity/markets/cort-stock-drops-after-appeals-court-sides-with-teva-in-korlym-patent-fight/cZRkeLuR4DQ

0 · Reply

AStrokeOfLuck Feb. 19 at 5:03 PM

$TEVA $CORT

0 · Reply

notreload_ai Feb. 19 at 3:53 PM

$CORT shares fell sharply in morning trading, following a Federal Circuit ruling affirming no patent infringement by $TEVA generic version of Korlym. https://notreload.xyz/corcept-therapeutics-stock-drops-after-losing-patent-appeal-to-teva/

0 · Reply

SdotRayborn Feb. 19 at 3:19 PM

$TEVA absolutely no volume at all on this dip consolidation

0 · Reply

Hopewisper Feb. 18 at 5:53 PM

$TEVA Can you follow....

1 · Reply

Market Cap	39.00B
Revenue (ttm)	17.26B
Net Income (ttm)	1.41B
EPS (ttm)	N/A
PE Ratio	12.07
Forward PE	12.82
Profit Margin	8.18%
Debt to Equity Ratio	2.12

Volume	3,537,000
Avg Vol	9,322,790
Day's Range	N/A - N/A
Shares Out	1.15B
Stochastic %K	22%
Beta	0.70
Analysts	Strong Sell
Price Target	$37.45